AgingResearch.NewsJoin free

SARS-CoV-2 IgG antibodies

Biomarker

1 paper1 finding

  • Human trial1

Interventions

1

Everolimus

upin humans1

1 study

  1. Everolimus increases SARS-CoV-2 IgG antibodies in humans (P = 0.004 and P < 0.001).

    “Levels of severe acute respiratory syndrome coronaVirus 2 IgG antibodies were significantly higher at both time points in the everolimus group ( P = 0.004 and P < 0.001).”

    Human trialelderly kidney transplant recipients after COVID-19 mRNA vaccination

    Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil-containing Immunosuppressive Regimens

    Transplantation11 May 2022

More on Everolimus

Latest

Related